Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 8/20 | 0.42 |
| ▸ | PYGL | P06737 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995283 | 0.89 | C3AR1 (0.42) | C3AR1FOLH1TGM2CASR | |
| SCHEMBL4566055 | 0.88 | C3AR1 (0.45) | C3AR1PDPK1 | |
| SCHEMBL4991622 | 0.88 | C3AR1 (0.45) | C3AR1PDPK1 | |
| SCHEMBL4986550 | 0.86 | C3AR1 (0.41) | C3AR1PYGLCYP2C9PDPK1 | |
| SCHEMBL4990654 | 0.85 | C3AR1 (0.45) | C3AR1FOLH1PDPK1TGM2 | |
| SCHEMBL4988251 | 0.84 | PDPK1 (0.45) | C3AR1BRD4PDPK1 | |
| SCHEMBL4989584 | 0.84 | C3AR1 (0.40) | C3AR1PYGLCYP2C9PDPK1 | |
| SCHEMBL4986529 | 0.83 | C3AR1 (0.43) | C3AR1FOLH1PDPK1TGM2 | |
| SCHEMBL4425979 | 0.82 | PADI1 (0.40) | C3AR1PDPK1 | |
| SCHEMBL4992633 | 0.82 | C3AR1 (0.42) | C3AR1BRD4FOLH1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | C3AR1 1/4885PYGL 1070/4885CYP2C9 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.